TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company ...

Expected Upcoming, Value-Driving Milestones Metastatic Pancreatic Ductal Adenocarcinoma Phase 1b/2 Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab with TLR-3 Agonist Ampligen in Patients ...

Equels. Recent Highlights Expected Upcoming, Value-Driving Milestones Metastatic Pancreatic Ductal Adenocarcinoma Phase 1b/2 Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab with TLR-3 ...

Dar/Nairobi. A ground-breaking HIV clinical trial in Africa has demonstrated that some women can control the virus without ...

This is a toll-like receptor, and we'll go into a little bit more about what that, what this toll or agonist is about. It's an immunotherapy drug candidate called Entolimod, and we acquired a ...

Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8656, Japan Department of Bioengineering, Graduate School of Engineering, The ...

Now, the researchers have uncovered a surprising twist in finding that these TLR-like LRR proteins serve a structural role, acting as molecular glue that binds other slime proteins together.

Toll-like receptor. Toll-like receptors (TLRs) are one of the largest and best-studied families of pattern-recognition receptors of the innate immune system. TLRs recognize pathogen- and danger ...

Recent pharmacological advances and clinical trials show that unimolecular co-agonists that target the receptors for the incretins – GIP and glucagon-like peptide 1 (GLP-1) – offer more effective ...

State officials are warning Americans not to respond to a surge of scam road toll collection texts. The texts impersonating state road toll collection agencies attempt to get phone users to reveal ...